Drug · DIN 02521202
IMATINIB
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 29, 2024; first marketed April 29, 2024.
- Drug Identification Number (DIN)
- 02521202
- Company (DIN owner)
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Imatinib L01EA01
- Class
- Human
- Record last updated
- July 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IMATINIB (IMATINIB MESYLATE) | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 5, 2023: NOC 32273Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Manufacturers
- October 13, 2021: NOC 26831Abbreviated New Drug Submission (ANDS) · Administrative: Licensing Agreement Between Two Companies
Other DINs named IMATINIB
- DIN 02504596 · Marketed
- DIN 02504618 · Marketed
- DIN 02521210 · Marketed